Keyword Analysis & Research: luspatercept mf
Keyword Research: People who searched luspatercept mf also searched
Search Results related to luspatercept mf on Search Engine
-
A Phase 2 Study of Luspatercept in Patients with Myelofibrosis
https://ashpublications.org/blood/article/134/Supplement_1/557/426593/A-Phase-2-Study-of-Luspatercept-in-Patients-with
WEBNov 13, 2019 · In this heavily transfused population there are severely limited treatment options; effective treatment for anemia in MF is a critically unmet medical need. … Author: Aaron T. Gerds, Alessandro M. Vannucchi, Francesco Passamonti, Marina Kremyanskaya, Jason R. Gotlib,... Publish Year: 2019
Author: Aaron T. Gerds, Alessandro M. Vannucchi, Francesco Passamonti, Marina Kremyanskaya, Jason R. Gotlib,...
Publish Year: 2019
DA: 27 PA: 74 MOZ Rank: 38
-
Luspatercept in Patients with Lower-Risk …
https://www.nejm.org/doi/full/10.1056/NEJMoa1908892
WEBPublished January 8, 2020. N Engl J Med 2020;382: 140 - 151. DOI: 10.1056/NEJMoa1908892. VOL. 382 NO. 2. Abstract. Background. … Author: Pierre Fenaux, Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia-Manero, Rena Buckst... Publish Year: 2020
Author: Pierre Fenaux, Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia-Manero, Rena Buckst...
Publish Year: 2020
DA: 17 PA: 33 MOZ Rank: 73
-
Safety and efficacy of luspatercept for the treatment of anemia in
https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.7016
WEBMay 31, 2023 · Abstract. 7016. Background: Many patients (pts) with myelofibrosis (MF) experience anemia resulting from disease or JAK inhibitor therapy. The open-label, …
DA: 52 PA: 48 MOZ Rank: 59
-
Luspatercept - StatPearls - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK560635/
WEBJul 10, 2023 · Luspatercept is a medication used to manage and treat anemia in myelodysplastic syndromes, primary myelofibrosis, and beta … Affiliations: Kern Medical Center
Affiliations: Kern Medical Center
DA: 93 PA: 53 MOZ Rank: 44
-
Predictive Biomarkers of Response to Luspatercept in Patients …
https://ashpublications.org/blood/article/142/Supplement%201/6330/506173/Predictive-Biomarkers-of-Response-to-Luspatercept
WEBNov 28, 2023 · Luspatercept is a transforming growth factor-β (TBF-β) family ligand trap that inhibits the TGF-β-Smad signaling axis and promotes late-stage erythropoiesis. …
DA: 47 PA: 88 MOZ Rank: 100
-
Next Generation Therapeutics for the Treatment of …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146033/
WEBApr 27, 2021 · A phase III, placebo-controlled trial of luspatercept in MF patients with anemia receiving ruxolitinib is currently being planned (NCT04717414). Sotatercept …
DA: 71 PA: 58 MOZ Rank: 86
-
Long-Term Efficacy and Safety of Luspatercept for …
https://ascopubs.org/doi/10.1200/JCO.21.02476
WEBAug 23, 2022 · We report long-term luspatercept safety and efficacy in 108 patients with LR-MDS in the PACE-MDS study, including 44 non-RS and 34 non–transfusion-dependent or previously untreated patients. The …
DA: 61 PA: 32 MOZ Rank: 56
-
Luspatercept for the treatment of anemia in …
https://ashpublications.org/blood/article/133/8/790/260592/Luspatercept-for-the-treatment-of-anemia-in
WEBFeb 21, 2019 · Luspatercept (and sotatercept), ligand traps that particularly inhibit GDF11, lead to RBC transfusion independence in 10% to 50% of lower-risk MDSs resistant to …
DA: 77 PA: 7 MOZ Rank: 34
-
Luspatercept: A New Tool for the Treatment of Anemia …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624301/
WEBOct 9, 2022 · Luspatercept, a fusion protein consisting of ActRIIB, a modified activin receptor IIB and a member of the TGF-β superfamily, and IgG1, the Fc domain of human …
DA: 77 PA: 64 MOZ Rank: 18
-
Safety and efficacy of luspatercept for the treatment of …
https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.7016
WEBConclusions: In pts with MF, the safety profile of LUSPA was consistent with previous studies and efficacy results showed promising improvements in anemia and transfusion …
DA: 99 PA: 25 MOZ Rank: 24
